TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01954992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide
Description: Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
Study: NCT00760123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy and Educational strategy
Description: Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy

Intervention type: OTHER
Group type: OTHER
Intervention: Early Physical Therapy and Educational strategy
Description: Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy
Study: NCT02208479

Intervention type: OTHER
Intervention: Non invasive ultrasound measurement of the diaphragm thickness during breathing
Study: NCT03824288

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound
Description: The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The landmark technique
Description: A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
Study: NCT03475368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
Study: NCT04288219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Positive Pressure Ventilation
Description: Continuous positive airway pressure delivered by face mask at 10cmH2O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine 30mg, Pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 30mg, Pharmacotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplemental oxygen
Description: supplemental oxygen
Study: NCT01366664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence 2
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence 1
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
Study: NCT03400124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISBCS
Description: The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSBCS
Description: The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
Study: NCT03324035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Administer to both arms on as needed scheme, to a maximum of 150mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Administer to both arms on as needed scheme, to a maximum of 150mg/day.
Study: NCT00771446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD plus standard of care treatment
Description: ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
Study: NCT04594759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Participants will be getting isotretinoin (1-1.5 mg/kg/week)
Study: NCT03830866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion every 4 weeks
Study: NCT00000255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Study: NCT02753036

Intervention type: DRUG
Intervention: Chemotherapy
Description: standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
Study: NCT02807064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacteria
Description: 0.5 ml per os all days for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0,5 ml per os all days for 2 months
Study: NCT01142609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eGet
Description: eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
Study: NCT02557386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mL
Description: Levobupivacaine 0.25% 5 mL in adductor canal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mL
Description: Levobupivacaine 0.25% 10 mL in adductor canal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 15 mL
Description: Levobupivacaine 0.25% 15 mL in adductor canal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 20 mL
Description: Levobupivacaine 0.25% 20 mL in adductor canal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 25 mL
Description: Levobupivacaine 0.25% 25 mL in adductor canal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 30 mL
Description: Levobupivacaine 0.25% 30 mL in adductor canal nerve block
Study: NCT00663728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg Vardenafil taken orally 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03830866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Study: NCT02415439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15
Study: NCT00648024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agrylin® Capsules 1 mg
Description: 1mg, single dose fasting
Study: NCT04572139

Intervention type: DIAGNOSTIC_TEST
Intervention: Pituitary stimulation test
Description: Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH

Intervention type: DIAGNOSTIC_TEST
Intervention: Pituitary stimulation test
Description: Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
Study: NCT02415439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15
Study: NCT03830866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care
Study: NCT00381173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Description: Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
Study: NCT03559348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: TS-1, Leucovorin and Gemcitabine
Description: Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
Study: NCT04572139

Intervention type: DIAGNOSTIC_TEST
Intervention: Pituitary stimulation test
Description: Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
Study: NCT03010618

Intervention type: OTHER
Group type: OTHER
Intervention: Hall technique stainless steel crowns
Description: Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
Study: NCT03220425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Study: NCT01094249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium ER/paliperidone ER
Description: Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
Study: NCT01677013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMMCT
Description: Bone marrow mononuclear cell transplantation via selective catheterization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMMCT
Description: Bone marrow mononuclear cell transplantation via selective catheterization
Study: NCT00109759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RagweedMATAMPL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01700478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol + vasopressin
Description: 400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin was used in all patients during surgery.
Study: NCT00207194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Telephone Program
Description: The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Behavior Education
Description: Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Behavior Education
Description: Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
Study: NCT00822393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 4 x 0.8 mg/kg/d Intravenous Day -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 10 g/m2/d Intravenous Day -4, -3, -2
Study: NCT01931527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Study: NCT03870113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinated group
Description: Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
Study: NCT03606720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic stabilization exercises
Description: special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic stabilization exercises
Description: special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
Study: NCT00522444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: 6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline
Description: standard of care
Study: NCT01100879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Study: NCT03634345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Day 1: PF-04965842 administered
Description: Period 1: Single administration of 100 mg PF 04965842.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Cohort 1: Fluvoxamine & PF-04965842
Description: Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
Study: NCT03522337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual pedagogy (social stories)
Description: Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional leaflets
Description: Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
Study: NCT03634345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Cohort 2: Fluconazole & PF-04965842
Description: Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
Study: NCT03744078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley balloon catheter
Description: 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
Study: NCT03459352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO
Description: Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction.
Study: NCT02049021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA SPECTRUM 5000Q ECT

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ECT
Description: Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
Study: NCT02794935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham IMT
Description: Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
Study: NCT01733147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 polyunsaturated fatty acids
Description: 3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
Study: NCT00841360

Intervention type: OTHER
Intervention: Index Recruiter
Description: Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.

Intervention type: OTHER
Intervention: Index Recruiter
Description: Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.

Intervention type: OTHER
Intervention: Index Recruiter
Description: Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.

Intervention type: OTHER
Intervention: Friendship Network Member
Description: Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.